URC-102 is a Small Molecule owned by C&C Research Laboratories, and is involved in 8 clinical trials, of which 5 were completed, and 3 are planned.
URC-102 acts by inhibiting urate transporter 1 (URAT1). URC102 promotes the excretion of uric acid by selectively inhibiting URAT1. Consequently, URC102 potently decreases serum uric acid resulting in therapeutic effect.
The revenue for URC-102 is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the URC-102 NPV Report.
URC-102 is under development for the treatment of gout with hyperuricemia. The drug candidate is administered orally. URC102 is a small molecule and acts by targeting urate transporter protein URAT1 (solute carrier family 22 member 12). It is a new molecular entity (NME).
Simcere Pharmaceutical Group Overview
Simcere Pharmaceutical Group (Simcere) is a pharmaceutical company discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas such as anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle, and others. Its product portfolio includes recombinant human endostatin injection, palonosetron hydrochloride injection, nedaplatin for injection, fluorouracil implants and lyvamlodipine besylate tablets, among others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low end generics and APIs to innovative medicines. The company’s precision medicine sector, Simcere diagnostics had strategic partnership t with Agena bioscience focused on Agena’s Massarray System for companion diagnostics and pharmacogenetic testing in China. Simcere is headquartered in Nanjing, Jiangsu, China
The company reported revenues of (Renminbi) CNY4,999.7 million for the fiscal year ended December 2021 (FY2021), an increase of 10.9% over FY2020. In FY2021, the company’s operating margin was 29%, compared to an operating margin of 20.6% in FY2020. In FY2021, the company recorded a net margin of 30.1%, compared to a net margin of 14.8% in FY2020.
Quick View – URC-102
|Highest Development Stage|